Cencora, Inc. (NYSE:COR) Shares Sold by Mattern Capital Management LLC

Mattern Capital Management LLC lowered its holdings in Cencora, Inc. (NYSE:COR) by 1.3% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 48,698 shares of the company’s stock after selling 653 shares during the period. Cencora makes up 1.4% of Mattern Capital Management LLC’s holdings, making the stock its 9th biggest holding. Mattern Capital Management LLC’s holdings in Cencora were worth $10,941,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the business. Dash Acquisitions Inc. acquired a new position in shares of Cencora in the fourth quarter valued at approximately $176,000. Concurrent Investment Advisors LLC grew its holdings in shares of Cencora by 4.5% in the fourth quarter. Concurrent Investment Advisors LLC now owns 8,046 shares of the company’s stock valued at $1,808,000 after purchasing an additional 349 shares in the last quarter. Bryn Mawr Capital Management LLC grew its holdings in shares of Cencora by 335.4% in the fourth quarter. Bryn Mawr Capital Management LLC now owns 25,863 shares of the company’s stock valued at $5,811,000 after purchasing an additional 19,923 shares in the last quarter. TimesSquare Capital Management LLC grew its holdings in shares of Cencora by 2.9% in the fourth quarter. TimesSquare Capital Management LLC now owns 544,248 shares of the company’s stock valued at $122,282,000 after purchasing an additional 15,464 shares in the last quarter. Finally, Convergence Investment Partners LLC grew its holdings in shares of Cencora by 27.9% in the fourth quarter. Convergence Investment Partners LLC now owns 7,935 shares of the company’s stock valued at $1,783,000 after purchasing an additional 1,733 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Activity at Cencora

In related news, EVP Silvana Battaglia sold 1,678 shares of the company’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the sale, the executive vice president now owns 20,329 shares in the company, valued at $4,649,648.88. This represents a 7.62 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Steven H. Collis sold 50,000 shares of the company’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the completion of the sale, the chairman now owns 326,557 shares of the company’s stock, valued at approximately $79,670,111.29. This trade represents a 13.28 % decrease in their position. The disclosure for this sale can be found here. 10.80% of the stock is owned by insiders.

Analysts Set New Price Targets

COR has been the subject of a number of research reports. Wells Fargo & Company lifted their price objective on shares of Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a report on Wednesday, January 29th. Robert W. Baird lifted their price target on shares of Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Evercore ISI lifted their price target on shares of Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research note on Thursday, February 6th. Mizuho assumed coverage on shares of Cencora in a research note on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price target for the company. Finally, Barclays lifted their price target on shares of Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $277.90.

Cencora Stock Down 0.8 %

Shares of NYSE:COR opened at $243.42 on Friday. The company has a market capitalization of $47.20 billion, a PE ratio of 34.63, a P/E/G ratio of 1.29 and a beta of 0.49. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $262.26. The firm has a 50 day simple moving average of $239.34 and a 200-day simple moving average of $237.46.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, equities analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 3rd. Stockholders of record on Friday, February 14th will be given a dividend of $0.55 per share. The ex-dividend date of this dividend is Friday, February 14th. This represents a $2.20 annualized dividend and a dividend yield of 0.90%. Cencora’s dividend payout ratio is presently 31.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.